64 results
Page 2 of 4
8-K
EX-99.1
t2v v9qjku2aed0cdi
22 Jul 21
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein
7:30am
8-K
EX-10.1
yicpd
22 Jul 21
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein
7:30am
8-K
EX-10.2
x2uvrb
22 Jul 21
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein
7:30am
DEFA14A
alxl8myzu305o85
26 Apr 21
Additional proxy soliciting materials
4:22pm
8-K
EX-1.1
xhopc 7c9u
18 Dec 20
Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock
6:30am
8-K
EX-99.1
vm4l1 qdzwkfqz2w1
29 May 20
Arvinas Releases Updated Dose Escalation Data from Clinical Trial of PROTAC® Protein Degrader
7:06am
DEFA14A
e2hvul0 twf9
20 May 20
Additional proxy soliciting materials
4:59pm
DEFA14A
6kinaoj twe9gf407y5
21 Apr 20
Additional proxy soliciting materials
5:05pm
8-K
EX-1.1
rhj7g28n
12 Nov 19
Arvinas, Inc. Announces Pricing of Public Offering of Common Stock
4:02pm
8-K
EX-99.1
ttti9b2w2og
23 Oct 19
Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC® Targeted Protein Degraders
6:39am